Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating and {REMOVEPT} price target on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments